Madrigal Pharmaceuticals MDGL reported a fourth-quarter 2025 loss of $2.57 per share, in contrast to the Zacks Consensus ...

Conshohocken’s Madrigal inks a $4B-plus global deal to expand its MASH drug pipeline beyond blockbuster Rezdiffra.

Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human ...

Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more ...

POWHATAN, Va. ( WWBT /Gray News) - A Virginia grandfather received a life-saving donation from a family member: his ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults, with about 30% of cases progressing to metabolic dysfunction-associated steatohepatitis (MASH), ...

On Dec. 23, 2025, Brian Walls received a Christmas miracle.

Madrigal is eying an expansion of Rezdiffra’s capabilities via combination with precision siRNA gene silencing.

Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidates, expanding MASH ...

CNW/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing ...

Here's a list of factors that are contributing to the rise in NAFLD cases, particularly in India, which can lead to more serious liver complications if left unchecked.

Ribo and Ribocure enter exclusive global licensing agreement with Madrigal for novel siRNA therapeutics targeting MASH: Suzhou, China Thursday, February 12, 2026, 15:00 Hrs [IST] ...